+ Watch OXGN
on My Watchlist
A biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases.
Appropriate for a rebound right about now
Gut feeling - following a zz play.
Zybrestat, when used in combination with Roche's (RHHBY) Avastin, delayed the re-growth of ovarian cancer, in recent phase II study. The potential for significant upside exists on this one, and management obvious believes in itself holding a large insider position.
new data on ovarian cancer (GOG Study); new chairman of the board
An extremely high growth period for this company's stock is starting to occur. It is extremely under valued. The company's breast cancer drug has positive trials.
I couldn't let the latest biopharma massacre go by without at least one correction outperform. Oxigene is of course extremely speculative but at a fully diluted market cap of about 20M and preliminary data from the GOG 186I trial of Zybrestat for ovarian cancer expected this half this stub should stay volatile ahead of topline data release.
Sadly I own this company.....
This will be a hot stock to day trade. Will be around 5 dollars in near future.
UP UP UP EXPLOSION!
New financing and need more Falcon data
I see it that this drud is going to finish ahead and that the FDA will aprove it and this stock is going to sky rocket if i where you I would buy buy buy
Science: Destroys in minutes ALL blood vessels of tumor!while preserving ALL other healthy cells!! NO side effects:http://www.wsw.com/webcast/rrshq10/oxgn/3__Slide16.JPGOXGN SAFETY:Lazard pres.Seasoned and creditentialled Mgt Team under Dr. Richard Chin who guided two of Genentechs current blockbusters: Avastin & Lucentis. In his 3rd month as CEO downsized co 33% and focused strategy of timely executions.Poised for Success is OXGN's Mantra.$4+mln of open mkt purchases by mgt team! $65K during Aug 5-10 by newest director Fickling.Indeed rare to find a $100 mln Mkt Cap. oncology play IN Phase THREE!
I am not smart enough to figure out which drugs will be good or bad. What will pass phase III trials, etc. But, what I do know is that when a biotech stock has tons of insiders who know the drug business buying up shares like crazy and have a lung cancer product that they can charge whatever they would want, it is worthy of buying.This is not just a caps pick but, one of my larger personal holdings.
i heard good news about this one.
Favorable news from pipeline in December. Things have finally settled down now.
Clinical trials almost done.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions